Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma.

Pediatric Blood & CancerEarly View e30430 LETTER TO THE EDITOR Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma Claire Geurten, Claire Geurten Department of Paediatric Haematology/Oncology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UK Department of Paediatric Haematology/Oncology, Centre Hospitalier Universitaire de Liège, Liège, BelgiumSearch for more papers by this authorJulie Errington, Julie Errington Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UKSearch for more papers by this authorShelby Barnett, Shelby Barnett Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UKSearch for more papers by this authorHiten Patel, Hiten Patel Department of Paediatric Radiology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorSaqib Noor, Saqib Noor Department of Paediatric Orthopaedic Surgery, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorVrinda Saraff, Vrinda Saraff Department of Paediatric Endocrinology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorGareth J. Veal, Gareth J. Veal Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UKSearch for more papers by this authorSusanne A. Gatz, Corresponding Author Susanne A. Gatz [email protected] Department of Paediatric Haematology/Oncology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UK Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK Correspondence Susanne A. Gatz, Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. Email: [email protected]Search for more papers by this author Claire Geurten, Claire Geurten Department of Paediatric Haematology/Oncology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UK Department of Paediatric Haematology/Oncology, Centre Hospitalier Universitaire de Liège, Liège, BelgiumSearch for more papers by this authorJulie Errington, Julie Errington Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UKSearch for more papers by this authorShelby Barnett, Shelby Barnett Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UKSearch for more papers by this authorHiten Patel, Hiten Patel Department of Paediatric Radiology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorSaqib Noor, Saqib Noor Department of Paediatric Orthopaedic Surgery, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorVrinda Saraff, Vrinda Saraff Department of Paediatric Endocrinology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorGareth J. Veal, Gareth J. Veal Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UKSearch for more papers by this authorSusanne A. Gatz, Corresponding Author Susanne A. Gatz [email protected] Department of Paediatric Haematology/Oncology, Birmingham Women and Children's NHS Foundation Trust, Birmingham, UK Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK Correspondence Susanne A. Gatz, Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. Email: [email protected]Search for more papers by this author First published: 27 May 2023 https://doi.org/10.1002/pbc.30430Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Steliarova-Foucher E, Colombet M, Ries L, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet North Am Ed. 2017; 18: 719- 731. 2Smith V, Foster J. High-risk neuroblastoma treatment review. Children. 2018; 5: 114. 3Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst. 1982; 68(4): 589- 596. 4Reynolds CP, Kane DJ, Einhorn PA, et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res. 1991; 366: 203- 211. 5Villablanca JG, Khan AA, Avramis VI, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995; 13: 894- 901. 6Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341(16): 1165- 1173. 7Veal GJ, Errington J, Rowbotham SE, et al. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res. 2013; 19(2): 469- 479. 8Simon T, Hero B, Schulte J, et al. 2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors. Klin Padiatr. 2017; 229: 147- 167. 9Ladenstein R. High-risk neuroblastoma study 1.5 of SIOP-Europe (SIOPEN). International Society of Pediatric Oncology European Neuroblastoma High Risk; 2014: 132- 134. 10Veal GJ, Tweddle DA, Visser J, et al. Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: a randomized crossover clinical trial. Cancers. 2021; 13(8): 1868. 11Khan AA, Villablanca JG, Reynolds CP, et al. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol. 1996; 39: 34- 41. 12Veal GJ, Cole M, Errington J, et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - study of the United Kingdom Children's Cancer Study Group. Br J Cancer. 2007; 96(3): 424- 431. 13Miziołek B, Bergler-Czop B, Stańkowska A, Brzezińska-Wcisło L. The safety of isotretinoin treatment in patients with bone fractures. Adv Dermatol Allergol. 2019; 36: 18- 24. 14Hotchkiss CE, Latendresse J, Ferguson SA. Oral treatment with retinoic acid de-creases bone mass in rats. Comp Med. 2006; 56: 502- 511. 15Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002; 287: 47- 54. 16Michaëlsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. 2003; 348: 287- 294. 17Mata-Granados JM, Cuenca-Acevedo JR, Luque de Castro MD, et al. Vitamin D insufficiency together with high serum levels of vitamin A increases the risk for osteoporosis in postmenopausal women. Arch Osteoporos. 2013; 8: 124. 18Caire-Juvera G, Ritenbaugh C, Wactawski-Wende J, et al. Vitamin A and retinol intakes and the risk of fractures among participants of the Women's Health Initiative Observational Study. Am J Clin Nutr. 2009; 89: 323- 330. 19Koh K-N, Jeon JY, Park S-S, et al. Physeal abnormalities in children with high-risk neuroblastoma intensively treated with/without 13-cis-retinoic acid. J Pediatr Orthop. 2021; 41(9): e841- e848. Early ViewOnline Version of Record before inclusion in an issuee30430 ReferencesRelatedInformation